Market closedNon-fractional
Arvinas/ARVN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Arvinas
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
Ticker
ARVN
Sector
Healthcare
Trading on
NASDAQ
Industry
Pharmaceuticals
Headquarters
New Haven, United States
Employees
445
Website
www.arvinas.com
Arvinas Metrics
BasicAdvanced
$2B
Market cap
-
P/E ratio
-$5.90
EPS
1.95
Beta
-
Dividend rate
Price and volume
Market cap
$2B
Beta
1.95
Financial strength
Current ratio
4.943
Quick ratio
4.885
Long term debt to equity
0.18
Total debt to equity
0.426
Management effectiveness
Return on assets (TTM)
-20.78%
Return on equity (TTM)
-63.32%
Valuation
Price to revenue (TTM)
24.335
Price to book
3.25
Price to tangible book (TTM)
3.25
Price to free cash flow (TTM)
-4.874
Growth
Revenue change (TTM)
-48.11%
Earnings per share change (TTM)
4.49%
3-year revenue growth (CAGR)
50.16%
3-year earnings per share growth (CAGR)
21.42%
What the Analysts think about Arvinas
Analyst Ratings
Majority rating from 20 analysts.
Arvinas Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$25M
-67.77%
Net income
-$69M
-81.11%
Profit margin
-274.30%
-41.38%
Arvinas Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$1.25
-$1.18
-$2.53
-$0.97
-
Expected
-$1.65
-$1.58
-$1.27
-$1.42
-$0.86
Surprise
-24.19%
-25.12%
99.55%
-31.57%
-
Arvinas News
AllArticlesVideos
Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer
GlobeNewsWire·1 month ago
Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2
GlobeNewsWire·1 month ago
Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D.
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Arvinas stock?
Arvinas (ARVN) has a market cap of $2B as of July 25, 2024.
What is the P/E ratio for Arvinas stock?
The price to earnings (P/E) ratio for Arvinas (ARVN) stock is 0 as of July 25, 2024.
Does Arvinas stock pay dividends?
No, Arvinas (ARVN) stock does not pay dividends to its shareholders as of July 25, 2024.
When is the next Arvinas dividend payment date?
Arvinas (ARVN) stock does not pay dividends to its shareholders.
What is the beta indicator for Arvinas?
Arvinas (ARVN) has a beta rating of 1.95. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Arvinas stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.